Cocrystal Pharma (FRA:8CC) Quality Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:8CC Cocrystal Pharma Inc FRA:8CC
35 GF Score
Price €0.94
GF Value €2.43
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Cocrystal Pharma Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Cocrystal Pharma Quality Rank Related Terms

FRA:8CC
35GF Score
Cocrystal Pharma Inc FRA:8CC
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Cocrystal Pharma (FRA:8CC) Overvalued in 2026?

Based on GuruFocus' analysis, Cocrystal Pharma stock appears to be undervalued. The current stock price of €0.94 is trading 61.3% below its estimated GF Value™ of €2.43. GuruFocus considers Cocrystal Pharma to be Possible Value Trap.

Key valuation signals for FRA:8CC:

  • Quality Rank:
  • GF Value™: €2.43 vs. price of €0.94 (61.3% below fair value)
  • GF Score™: 35/100 with 4 warning signs

No single metric tells the full story. See the FRA:8CC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cocrystal Pharma Business Description

Other Exchanges COCP:USA
Address 19805 North Creek Parkway, Bothell, WA, USA, 98011
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). The company has one reportable and operating segment dedicated to the research and development company's novel orally administered antiviral influenza candidate. The company has pipeline products for diseases like : Influenza, Norovirus, Coronavirus, Respiratory Viruses, and Hepatitis C.
35GF Score

Get the complete analysis for FRA:8CC

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.94
Price
€2.43
GF Value